307 related articles for article (PubMed ID: 18755588)
1. Structure-guided design of substituted aza-benzimidazoles as potent hypoxia inducible factor-1alpha prolyl hydroxylase-2 inhibitors.
Frohn M; Viswanadhan V; Pickrell AJ; Golden JE; Muller KM; Bürli RW; Biddlecome G; Yoder SC; Rogers N; Dao JH; Hungate R; Allen JR
Bioorg Med Chem Lett; 2008 Sep; 18(18):5023-6. PubMed ID: 18755588
[TBL] [Abstract][Full Text] [Related]
2. Dipeptidyl-quinolone derivatives inhibit hypoxia inducible factor-1α prolyl hydroxylases-1, -2, and -3 with altered selectivity.
Murray JK; Balan C; Allgeier AM; Kasparian A; Viswanadhan V; Wilde C; Allen JR; Yoder SC; Biddlecome G; Hungate RW; Miranda LP
J Comb Chem; 2010 Sep; 12(5):676-86. PubMed ID: 20666436
[TBL] [Abstract][Full Text] [Related]
3. Pharmacological characterization of 1-(5-chloro-6-(trifluoromethoxy)-1H-benzoimidazol-2-yl)-1H-pyrazole-4-carboxylic acid (JNJ-42041935), a potent and selective hypoxia-inducible factor prolyl hydroxylase inhibitor.
Barrett TD; Palomino HL; Brondstetter TI; Kanelakis KC; Wu X; Haug PV; Yan W; Young A; Hua H; Hart JC; Tran DT; Venkatesan H; Rosen MD; Peltier HM; Sepassi K; Rizzolio MC; Bembenek SD; Mirzadegan T; Rabinowitz MH; Shankley NP
Mol Pharmacol; 2011 Jun; 79(6):910-20. PubMed ID: 21372172
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design, synthesis, and SAR evaluation of a new series of 8-hydroxyquinolines as HIF-1alpha prolyl hydroxylase inhibitors.
Warshakoon NC; Wu S; Boyer A; Kawamoto R; Sheville J; Renock S; Xu K; Pokross M; Zhou S; Winter C; Walter R; Mekel M; Evdokimov AG
Bioorg Med Chem Lett; 2006 Nov; 16(21):5517-22. PubMed ID: 16931007
[TBL] [Abstract][Full Text] [Related]
5. Design and synthesis of a series of novel pyrazolopyridines as HIF-1alpha prolyl hydroxylase inhibitors.
Warshakoon NC; Wu S; Boyer A; Kawamoto R; Renock S; Xu K; Pokross M; Evdokimov AG; Zhou S; Winter C; Walter R; Mekel M
Bioorg Med Chem Lett; 2006 Nov; 16(21):5687-90. PubMed ID: 16908145
[TBL] [Abstract][Full Text] [Related]
6. Design and synthesis of substituted pyridine derivatives as HIF-1alpha prolyl hydroxylase inhibitors.
Warshakoon NC; Wu S; Boyer A; Kawamoto R; Sheville J; Bhatt RT; Renock S; Xu K; Pokross M; Zhou S; Walter R; Mekel M; Evdokimov AG; East S
Bioorg Med Chem Lett; 2006 Nov; 16(21):5616-20. PubMed ID: 16908149
[TBL] [Abstract][Full Text] [Related]
7. A novel class of prolyl hydroxylase inhibitors induces angiogenesis and exerts organ protection against ischemia.
Nangaku M; Izuhara Y; Takizawa S; Yamashita T; Fujii-Kuriyama Y; Ohneda O; Yamamoto M; van Ypersele de Strihou C; Hirayama N; Miyata T
Arterioscler Thromb Vasc Biol; 2007 Dec; 27(12):2548-54. PubMed ID: 17932321
[TBL] [Abstract][Full Text] [Related]
8. Novel 5-azaindole factor VIIa inhibitors.
Riggs JR; Hu H; Kolesnikov A; Leahy EM; Wesson KE; Shrader WD; Vijaykumar D; Wahl TA; Tong Z; Sprengeler PA; Green MJ; Yu C; Katz BA; Sanford E; Nguyen M; Cabuslay R; Young WB
Bioorg Med Chem Lett; 2006 Jun; 16(12):3197-200. PubMed ID: 16621549
[TBL] [Abstract][Full Text] [Related]
9. Design and synthesis of orally bioavailable benzimidazoles as Raf kinase inhibitors.
Ramurthy S; Subramanian S; Aikawa M; Amiri P; Costales A; Dove J; Fong S; Jansen JM; Levine B; Ma S; McBride CM; Michaelian J; Pick T; Poon DJ; Girish S; Shafer CM; Stuart D; Sung L; Renhowe PA
J Med Chem; 2008 Nov; 51(22):7049-52. PubMed ID: 18942827
[TBL] [Abstract][Full Text] [Related]
10. Short-term effects of pharmacologic HIF stabilization on vasoactive and cytotrophic factors in developing mouse brain.
Schneider C; Krischke G; Keller S; Walkinshaw G; Arend M; Rascher W; Gassmann M; Trollmann R
Brain Res; 2009 Jul; 1280():43-51. PubMed ID: 19450570
[TBL] [Abstract][Full Text] [Related]
11. 2-Aminobenzimidazoles as potent ITK antagonists: trans-stilbene-like moieties targeting the kinase specificity pocket.
Lo HY; Bentzien J; Fleck RW; Pullen SS; Khine HH; Woska JR; Kugler SZ; Kashem MA; Takahashi H
Bioorg Med Chem Lett; 2008 Dec; 18(23):6218-21. PubMed ID: 18930400
[TBL] [Abstract][Full Text] [Related]
12. Non-hypoxic activation of the negative regulatory feedback loop of prolyl-hydroxylase oxygen sensors.
Tug S; Delos Reyes B; Fandrey J; Berchner-Pfannschmidt U
Biochem Biophys Res Commun; 2009 Jul; 384(4):519-23. PubMed ID: 19427832
[TBL] [Abstract][Full Text] [Related]
13. A novel series of imidazo[1,2-a]pyridine derivatives as HIF-1alpha prolyl hydroxylase inhibitors.
Warshakoon NC; Wu S; Boyer A; Kawamoto R; Sheville J; Renock S; Xu K; Pokross M; Evdokimov AG; Walter R; Mekel M
Bioorg Med Chem Lett; 2006 Nov; 16(21):5598-601. PubMed ID: 16962772
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design and optimization of potent renin inhibitors on 5- or 7-azaindole-scaffolds.
Matter H; Scheiper B; Steinhagen H; Böcskei Z; Fleury V; McCort G
Bioorg Med Chem Lett; 2011 Sep; 21(18):5487-92. PubMed ID: 21840215
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel hydroxy-thiazoles as HIF-alpha prolyl hydroxylase inhibitors: SAR, synthesis, and modeling evaluation.
Tegley CM; Viswanadhan VN; Biswas K; Frohn MJ; Peterkin TA; Chang C; Bürli RW; Dao JH; Veith H; Rogers N; Yoder SC; Biddlecome G; Tagari P; Allen JR; Hungate RW
Bioorg Med Chem Lett; 2008 Jul; 18(14):3925-8. PubMed ID: 18579373
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of novel 2-amino-6-phenyl-pyrimido[5',4':5,6]pyrimido[1,2-a]benzimidazol-5(6H)-ones as potent and orally active inhibitors of lymphocyte specific kinase (Lck): synthesis, SAR, and in vivo anti-inflammatory activity.
Martin MW; Newcomb J; Nunes JJ; Boucher C; Chai L; Epstein LF; Faust T; Flores S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Kim JL; Middleton S; Morgenstern K; Oliveira-dos-Santos A; Patel VF; Powers D; Rose P; Tudor Y; Turci SM; Welcher AA; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Ermann M; Johnston D; Saluste CG
J Med Chem; 2008 Mar; 51(6):1637-48. PubMed ID: 18278858
[TBL] [Abstract][Full Text] [Related]
17. Biochemical characterization of human prolyl hydroxylase domain protein 2 variants associated with erythrocytosis.
Pappalardi MB; Martin JD; Jiang Y; Burns MC; Zhao H; Ho T; Sweitzer S; Lor L; Schwartz B; Duffy K; Gontarek R; Tummino PJ; Copeland RA; Luo L
Biochemistry; 2008 Oct; 47(43):11165-7. PubMed ID: 18834144
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and properties of the first all-aza analogue of a biologically active peptide.
Gante J; Krug M; Lauterbach G; Weitzel R; Hiller W
J Pept Sci; 1995; 1(3):201-6. PubMed ID: 9222997
[TBL] [Abstract][Full Text] [Related]
19. Novel complex crystal structure of prolyl hydroxylase domain-containing protein 2 (PHD2): 2,8-Diazaspiro[4.5]decan-1-ones as potent, orally bioavailable PHD2 inhibitors.
Deng G; Zhao B; Ma Y; Xu Q; Wang H; Yang L; Zhang Q; Guo TB; Zhang W; Jiao Y; Cai X; Zhang J; Liu H; Guan X; Lu H; Xiang J; Elliott JD; Lin X; Ren F
Bioorg Med Chem; 2013 Nov; 21(21):6349-58. PubMed ID: 24055079
[TBL] [Abstract][Full Text] [Related]
20. Aza-stilbenes as potent and selective c-RAF inhibitors.
McDonald O; Lackey K; Davis-Ward R; Wood E; Samano V; Maloney P; Deanda F; Hunter R
Bioorg Med Chem Lett; 2006 Oct; 16(20):5378-83. PubMed ID: 16890436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
